Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!

Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!

11 May 2017

Thank you so much

Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! Whether you registered online and fundraised, registered on the day and marched, worked on a volunteer Committee, donated prizes….you have contributed to getting the Big Data for Melanoma national Research Project happening!

What is the Big Data for Melanoma national Research Project?

This project, which is supported by Melanoma March 2016, 2017 and 2018 is about saving lives lost through system failure: not all patients obtain care that follows best practice. A national register of key outcomes in melanoma will enable everyone with a stake in melanoma prevention, detection and care to see where improvement is needed, and enable us all to learn how to change care for the better. This project will demonstrate in a suitable range of pilot sites that an Australian Clinical Outcomes Register for Melanoma is feasible, discover how it must work, and provide the business case to attract the expanded support necessary to apply and implement it nationally.

Melanoma is gradually becoming less common in the young, due to better sun protection, but overall there are 20-30yr left to run before melanoma rates fall substantially in Australia, no matter how much prevention improves. Our main weapons to control melanoma are early detection and prompt, effective treatment.

The national health cost burden of melanoma was estimated at $500m/yr from 2010 NSW data. Since then new, effective drug and immune treatments for metastatic melanoma have dramatically increased the cost of treating it, and careful application of these treatments after initial surgery promises to cure people whose melanoma would otherwise return after surgery. So the stakes for “getting it right” at each stage of melanoma have never been higher.

A great deal of effort is invested to describe to doctors and the community how best to diagnose and treat melanoma, notably in documents such as the Guidelines for Management of Cutaneous Melanoma (ACN 1997, 1999, 2010; 2017 under revision). However, as in all areas of health care, the evidence says that not all people with melanoma receive optimal treatment. For example, fewer than two thirds of melanomas in Victoria in 2000 were removed with a wide enough margin of skin, and in 2006 in NSW 21% still fell short. Only 17% of melanomas in NSW in 2006 were staged correctly using surgery to check the lymph nodes. Gaps such as this are a massive opportunity to save lives.

Clinical outcomes registers aim to track the most important steps of a patient’s treatment. If this is done across the nation, then research through the register can show where and why gaps exist, and therefore what can be done to change that for the better. The very process of collecting this information, and sharing it, has been shown to produce improvement in patient care.

This project aims to establish a pilot and prototype of a national clinical outcomes register for melanoma.

What’s happened so far?

The concept was circulated among the Australian melanoma research community (over 50 biomedical, translational and clinical researchers) in Dec 2015-Mar 2016, and received strong support.

The group that was originally consulted reconvened 28 Nov 2016 by teleconference in conjunction with a meeting of the national Cancer Australia Melanoma Guidelines Working Group. They agreed to proceed to design and launch a project that in 12-18 months would demonstrate feasibility of coordinated registration and data collection of key melanoma outcomes from selected participating centres in a range of contexts: melanoma centres, specialized private practices, skin cancer clinics and primary care.

Under an interim Steering Committee, a workshop was convened on 27 March 2017 at Melanoma Institute Australia that agreed on broad goals and authorized an Executive Group to launch the pilot project.

What does the pilot project look like?

The project aims to show the feasibility of coordinated registration and data collection of key melanoma outcomes from participating centres nationally, in a range of contexts: melanoma centres, specialized private practices, skin cancer clinics and primary care. These feasibility data and preliminary evidence obtained on outcomes would support accelerated applications to fund and establish the register nationally, to cover at least 98% of eligible patients.

In this pilot project, the key clinical outcomes to be registered will be, for new primary melanoma, the adequacy of:

  • diagnosis (biopsy type/success, time to excision, margins, staging)
  • definitive therapy (margins)
  • patient support

It is recognised that registration of patient support outcomes will likely require specific development to incorporate patient-recorded outcome measures (PROM). Since these are not yet widely adopted in clinical practice the register project will help drive these innovations in melanoma care.

Phase 1 of the project will, over six months:

  • finalise the Register governance, design and protocol
  • establish its team and support framework
  • select and commission participating sites, including ethical and governance approvals
  • select and commission the data collection platforms
  • engage stakeholders: health jurisdictions, cancer NGOs and community
  • plan for phased implementation options, dependent on securing further external funding
  • prepare applications for further competitive and non-competitive funding

Phase 2 will, based on available resources, by end 2018:

  • initiate and ramp up Register data collection in all pilot sites
  • collate and analyse process and performance data to test feasibility in each site against the goal of 98% coverage
  • identify barriers and enablers of Register performance
  • analyse and report evidence of the clinical outcomes in the register pilot sites.

 

 

 

MIA Co-Medical Director opens SMR Congress in USA
21 Nov 2019

MIA Co-Medical Director opens SMR Congress in USA

Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.

Highly Cited Researchers List names MIA Co-Medical Directors
20 Nov 2019

Highly Cited Researchers List names MIA Co-Medical Directors

MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.

MPA and MIA collaboration
07 Nov 2019

MPA and MIA collaboration

Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.

Community Fundraising October Wrap-Up
04 Nov 2019

Community Fundraising October Wrap-Up

It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.

Promising data for advanced melanoma patients
09 Oct 2019

Promising data for advanced melanoma patients

MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.

Melanoma Information Forum
04 Oct 2019

Melanoma Information Forum

We are delighted to partner with Melanoma Patients Australia to host a Melanoma Information Forum at The Poche Centre on 6th November.

Community Fundraising September Wrap-Up
02 Oct 2019

Community Fundraising September Wrap-Up

Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.

Notice for Supporters to Submit to PBAC
26 Sep 2019

Notice for Supporters to Submit to PBAC

Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.

Tune into Jay's Longest Melanoma March Channel 10 documentary
16 Sep 2019

Tune into Jay's Longest Melanoma March Channel 10 documentary

Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.

Professor Georgina Long Co-Medical Director named Women of Influence in Australian Financial Review Top 100 List
11 Sep 2019

Professor Georgina Long Co -Medical Director named Women of Influence in AFR Top 100 List

We are proud to announce that our Professor Georgina Long Co -Medical Director Melanoma Institute Australia has been named in the Top 100 Financial Review 2019 Women of Influence.

Community Fundraising August Wrap-Up
04 Sep 2019

Community Fundraising August Wrap-Up

It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships
02 Sep 2019

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships

They are a formidable team - in work and in play  –  and one set to make history on both fronts.

Melanoma Institute Australia hosts first SunSafe Student Ambassador Program for 2019
30 Aug 2019

Melanoma Institute Australia hosts SunSafe Student Ambassador Programs 2019

This week, Melanoma Institute Australia hosted the first of six SunSafe Student Ambassador Programs for 2019.

Tags: SunSafe
Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma
23 Aug 2019

Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma

Federal government urged to provide certainty of access to immunotherapy for high risk melanoma patients.

Team Melanoma smashes City2Surf
16 Aug 2019

Team Melanoma smashes City2Surf

We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!

Ready to run over melanoma at City2Surf 2019
08 Aug 2019

Ready to run over melanoma at City2Surf 2019

Lauren O'Brien tells us why she's running for a cause close to her heart

Community Fundraising July Wrap-Up
01 Aug 2019

Community Fundraising July Wrap-Up

MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in the month of July that are helping us move closer to our goal of zero deaths from melanoma.

Breast cancer drug may hold key to tackling most deadly type of melanoma
23 Jul 2019

Breast cancer drug may hold key to tackling most deadly type of melanoma

An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a type of breast cancer may hold the key to treating an aggressive and deadly form of melanoma.

MIA takes centre stage at leading cancer conference
05 Jun 2019

MIA takes centre stage at leading cancer conference

Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma is treated .

International Clinical Trials Day 2019
20 May 2019

International Clinical Trials Day 2019

Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.